Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine.

D'Souza AJ, Mar KD, Huang J, Majumdar S, Ford BM, Dyas B, Ulrich RG, Sullivan VJ.

J Pharm Sci. 2013 Feb;102(2):454-61. doi: 10.1002/jps.23422. Epub 2012 Dec 14.

PMID:
23242822
2.

Evaluation of the effect of syringe surfaces on protein formulations.

Majumdar S, Ford BM, Mar KD, Sullivan VJ, Ulrich RG, D'souza AJ.

J Pharm Sci. 2011 Jul;100(7):2563-73. doi: 10.1002/jps.22515. Epub 2011 Feb 11.

PMID:
21319164
3.

Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine.

Huang J, D'Souza AJ, Alarcon JB, Mikszta JA, Ford BM, Ferriter MS, Evans M, Stewart T, Amemiya K, Ulrich RG, Sullivan VJ.

Clin Vaccine Immunol. 2009 May;16(5):719-25. doi: 10.1128/CVI.00447-08. Epub 2009 Mar 4.

4.

Biophysical characterization and formulation of F1-V, a recombinant plague antigen.

D'Souza AJ, Ford BM, Mar KD, Sullivan VJ.

J Pharm Sci. 2009 Aug;98(8):2592-602. doi: 10.1002/jps.21652.

PMID:
19116945
5.

Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.

Huang J, Mikszta JA, Ferriter MS, Jiang G, Harvey NG, Dyas B, Roy CJ, Ulrich RG, Sullivan VJ.

Hum Vaccin. 2007 May-Jun;3(3):90-3. Epub 2007 May 13.

PMID:
17375001
6.

Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine.

Mikszta JA, Dekker JP 3rd, Harvey NG, Dean CH, Brittingham JM, Huang J, Sullivan VJ, Dyas B, Roy CJ, Ulrich RG.

Infect Immun. 2006 Dec;74(12):6806-10. Epub 2006 Oct 9.

7.

Formulation of a dry powder influenza vaccine for nasal delivery.

Garmise RJ, Mar K, Crowder TM, Hwang CR, Ferriter M, Huang J, Mikszta JA, Sullivan VJ, Hickey AJ.

AAPS PharmSciTech. 2006 Mar 10;7(1):E19.

8.

Formulation of a dry powder influenza vaccine for nasal delivery.

Garmise RJ, Mar K, Crowder TM, Hwang CR, Ferriter M, Huang J, Mikszta JA, Sullivan VJ, Hickey AJ.

AAPS PharmSciTech. 2006 Mar;7(1):E131-E137. doi: 10.1208/pt070119. Epub 2017 Mar 8.

9.

Noninvasive delivery technologies: respiratory delivery of vaccines.

Sullivan VJ, Mikszta JA, Laurent P, Huang J, Ford B.

Expert Opin Drug Deliv. 2006 Jan;3(1):87-95. Review.

PMID:
16370942
10.

Anthrax vaccine powder formulations for nasal mucosal delivery.

Jiang G, Joshi SB, Peek LJ, Brandau DT, Huang J, Ferriter MS, Woodley WD, Ford BM, Mar KD, Mikszta JA, Hwang CR, Ulrich R, Harvey NG, Middaugh CR, Sullivan VJ.

J Pharm Sci. 2006 Jan;95(1):80-96.

PMID:
16315230
11.

Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

Mikszta JA, Sullivan VJ, Dean C, Waterston AM, Alarcon JB, Dekker JP 3rd, Brittingham JM, Huang J, Hwang CR, Ferriter M, Jiang G, Mar K, Saikh KU, Stiles BG, Roy CJ, Ulrich RG, Harvey NG.

J Infect Dis. 2005 Jan 15;191(2):278-88. Epub 2004 Dec 15.

PMID:
15609239
12.

A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.

Huang J, Garmise RJ, Crowder TM, Mar K, Hwang CR, Hickey AJ, Mikszta JA, Sullivan VJ.

Vaccine. 2004 Dec 21;23(6):794-801.

PMID:
15542204
13.

Deaf women: experiences and perceptions of healthcare system access.

Steinberg AG, Wiggins EA, Barmada CH, Sullivan VJ.

J Womens Health (Larchmt). 2002 Oct;11(8):729-41.

PMID:
12570039
14.

The diagnostic interview schedule for deaf patients on interactive video: a preliminary investigation.

Steinberg AG, Lipton DS, Eckhardt EA, Goldstein M, Sullivan VJ.

Am J Psychiatry. 1998 Nov;155(11):1603-4.

PMID:
9812126
15.

Cultural and linguistic barriers to mental health service access: the deaf consumer's perspective.

Steinberg AG, Sullivan VJ, Loew RC.

Am J Psychiatry. 1998 Jul;155(7):982-4.

PMID:
9659872

Supplemental Content

Loading ...
Support Center